IDH2 and acute myeloid leukemia: In a phase 1b/2 clinical trial, 101 patients with newly diagnosed IDH2-mutated AML ineligible for induction therapy were randomized 2:1 to azacitidine 75 mg/m2 (days 1–7 of a 28-day cycle) plus enasidenib 100 mg daily (n = 68) versus azacitidine alone (n = 33) [85].